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ABSTRACT 
Aim: α1-blockers improve voiding symptoms through the reduction of prostatic and 
urethral smooth muscle tone; however, the underlying mechanism of improvement of 
storage symptoms is not known. Using a rat model of detrusor overactivity caused by 
cerebral infarction (CI), we undertook the present study to determine whether the effect 
of an α1-blocker, naftopidil, is dependent on the suppression of C-fiber afferents.  
Methods: To induce desensitization of C-fiber bladder afferents, we injected 
resiniferatoxin (0.3 mg/kg, RTX) subcutaneously to female Sprague-Dawley rats 2 days 
prior to left middle cerebral artery occlusion (MCAO) (RTX-CI rats). As controls we 
used rats without RTX treatment (CI rats). MCAO and insertion of a polyethylene 
catheter through the bladder dome were performed under halothane anesthesia. We 
investigated the effects on cystometrography of intravenous, intracerebroventricular, or 
intrathecal administration of naftopidil in conscious CI rats.  
Results: Bladder capacity (BC) was markedly reduced after MCAO in both RTX-CI 
and CI rats. Intravenous administration of naftopidil significantly increased BC in CI 
rats without an increase in residual volume, but it had no effects on BC in RTX-CI rats. 
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Intrathecal administration of naftopidil significantly increased BC in CI but not in 
RTX-CI rats. 
Conclusion: These results suggest that naftopidil has an inhibitory effect on C-fiber 
afferents in the lumbosacral spinal cord, improving BC during the storage phase. 
 
Abbreviations: CI, cerebral infarction; RTX, resiniferatoxin; MCAO, middle cerebral 
artery occlusion; BC, bladder capacity; BOO, bladder outlet obstruction; AR, 
adrenoceptors; i.v., intravenous; i.c.v., intracerebroventricular; i.t., intrathecal; ICA, 
internal carotid artery 
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INTRODUCTION 
   The voiding dysfunction accompanying bladder outlet obstruction (BOO) is due to 
mechanical compression induced by the enlarged prostate and to a dynamic component 
related to the contraction of the lower urinary tract caused by stimulated activity of the 
sympathetic nervous system [Shapiro et al., 1995]. The functional importance of 
α1-adrenoceptors (α1-ARs) in the sympathetic nerve terminals of the prostate has been 
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indicated, and dynamic obstruction has been shown to be mediated by α1-AR 
stimulation. α1-AR blockers are the most frequently prescribed therapeutic agents for 
elderly patients with voiding and storage symptoms. Currently, α1-ARs are generally 
subdivided into α1A-, α1B-, and α1D-AR subtypes [Bylund et al., 1994]. In the 
prostate gland, for example, the α1A-AR subtype is predominantly expressed [Price et 
al., 1993; Yazawa et al., 1993], and contraction of the human prostate in response to 
α1-AR stimulation is mediated by this subtype [Marshall et al., 1995]. The α1D-AR 
subtype is expressed in the detrusor, peripheral ganglia, and spinal cord in humans and 
rats [Somogyi et al., 1995; Malloy et al., 1998; Smith et al., 1999; Hampel et al., 2002]. 
Recently, involvement of the α1D-AR subtype in the storage symptoms has been 
indicated by some experimental findings [Hampel et al., 2002; Chen et al., 2005]. 
α1-AR blockers with significant affinity for the α1D-AR subtype are known to improve 
storage symptoms related to BOO; however, it is not clear why or how these agents 
relieve the overactive bladder [Sugaya et al., 2002]. α1-AR blockers act during the 
storage phase, allowing an increase of the bladder capacity and decreasing urgency; 
therefore, they may exert an inhibitory effect on afferent nerves.  
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   As an animal model of BOO, the rat with partial urethral obstruction reveals bladder 
hypertrophy, pre-micturition contraction, and increased bladder capacity [Malmgren et 
al., 1987; Igawa et al., 1994]. Pre-micturition contractions in the rat are spontaneous 
detrusor contractions during the storage phase that are not associated with micturition 
[Igawa et al., 1994]. The incidence of a positive ice water test mediated by C-fiber 
bladder afferents was significantly higher in subjects with BOO than in nonobstructed 
subjects [Chai et al., 1998]. These results indicate that increased activity of the afferent 
limb of the micturition reflex pathway, including C-fiber bladder afferents, is probably 
responsible for the development of detrusor overactivity in humans. Nevertheless, 
capsaicin-sensitive C-fiber afferents are not essential to induce pre-micturition 
contraction in rats with BOO [Tanaka et al., 2003]. Treatment with capsaicin prior to the 
creation of BOO did not decrease the frequency of pre-micturition contraction in the rat 
[Tanaka et al., 2003]. Detrusor overactivity in humans is likely to differ from 
pre-micturition contractions in rats with BOO. Therefore, it is not suitable to evaluate 
the effect of α1-AR blockers on detrusor overactivity in the rat model with BOO. The 
α1-AR blocker doxazosin did not markedly affect pre-micturition contraction or bladder 
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capacity [Ishizuka et al., 1996].  
   A rat model of detrusor overactivity due to cerebral infarction (CI) is widely known 
as a monitor tool for evaluating the usefulness of agents against bladder overactivity 
[Yokoyama et al., 1997]. To determine whether an α1-AR blocker can act on C-fiber 
afferents, it is necessary to compare the effect of the drug on bladder overactivity 
between C-fiber-desensitized and C-fiber-normal rats. Using this model, we studied the 
influence of intravenous (i.v.), intracerebroventricular (i.c.v.), and intrathecal (i.t.) 
naftopidil [Takei et al., 1999], an α1A- and α1D-AR blocker, on detrusor overactivity 
caused by cerebral infarction in rats with or without pretreatment with RTX. 
 
MATERIALS AND METHODS 
   Forty-eight female Sprague-Dawley rats, weighing 238-269 g (mean = 249 g), were 
used in this study. They were housed at a constant temperature (23 ± 2ºC) and humidity 
(50-60%) under a regular 12-hour light/dark schedule (lights on 7:00 AM - 7:00 PM). 
Tap water and standard rat chow were freely available. All experiments were performed 
in strict accordance with the guidelines of the Institutional Animal Care and Use 
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Committee. Before the experiment rats were trained to adapt to prolonged restraint. 
Pretreatment with resiniferatoxin 
   To induce desensitization of C-fiber bladder afferents, resiniferatoxin (RTX; 0.3 
mg/kg) was injected subcutaneously into female Sprague-Dawley rats 2 days prior to 
left middle cerebral artery occlusion (MCAO). RTX was dissolved in a vehicle of 10% 
ethanol and 90% saline. As controls we used rats without injection of RTX. 
Cystometrography (CMG) in conscious rats 
   Surgical anesthesia was induced and maintained using 2% halothane. CMGs in 
conscious rats were performed according to previously published methods [Yokoyama 
et al., 1997]. The CMG catheter was passed through a small incision at the apex of the 
bladder dome. The rats were placed in a restraining cage (Ballman Cage, KN-326 Type 
3; Natsume Seisakusho Co., Ltd., Tokyo, Japan) and allowed to recover from halothane 
anesthesia. The CMG catheter was connected to a pump (TE-311; Terumo Co. Ltd., 
Tokyo, Japan) for the continuous infusion of saline and to a pressure transducer 
(TP-200T; Nihon-Kohden Co., Ltd., Tokyo, Japan) by means of a polyethylene T-tube. 
Cystometric recording was achieved by infusing physiological saline at room 
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temperature into the bladder at a rate of 0.04 ml per minute and by collecting and 
measuring the saline voided from the urethral meatus to determine the voided volume. 
Evacuating the bladder through the cystometry catheter enabled us to measure the 
residual volume after the micturition reflex. The values of three cystometric parameters 
(bladder capacity, residual volume, and bladder contraction pressure) were obtained 
from each cystometry measurement. Bladder capacity was defined as the sum of the 
voided and residual volumes. Control cystometric recordings were performed 2 hours 
after surgical implantation of the cystometry catheter. 
Induction of cerebral infarction in rats 
   After control cystometric recordings were made, surgical anesthesia was induced 
and maintained using 2% halothane. Left MCAO were performed according to 
previously published methods [Yokoyama et al., 1997].  
Drug administration 
   For i.v. drug administration, the left jugular vein was cannulated (PE-10) 
immediately after MCA occlusion. Increasing doses of naftopidil (2.6x10-1 ~ 2.6x103 
nM/kg) were administered. The dose of 2.6x10 nM/kg is almost equivalent to serum 
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dose in humans after oral administration of 25 mg naftopidil in pharmacokinetics study 
[Ohki et al., 1996]. 
   For i.c.v. drug administration, the implantation of an injection tube into the right 
lateral ventricle was performed immediately after MCA occlusion. The rats were 
positioned in a stereotaxic frame, a scalp incision was made over the sagittal suture, and 
a hole (diameter about 1.0 mm) was drilled in the right parietal bone to expose the dural 
surface 1.0 mm lateral and 0 mm anterior from the bregma. A sterile stainless steel 
cannula (inside diameter: 0.3 mm, outside diameter: 0.6 mm, length: 10.5 mm) was 
lowered 5.3 mm ventrally from the skull surface with the end of a micromanipulator. By 
using a small screw placed in the skull as an anchor, the cannula was fixed to the skull 
with dental acrylic cement. Intracerebroventricular drug administration (5 µl/rat) 
occurred while the rats were conscious. 
   For i.t. administration, the occipital crest of the skull was exposed and the 
atlanto-occipital membrane was incised at the midline with the tip of an 18-gauge 
needle. A catheter (PE-10) was inserted through the slit and passed caudally to the L6 
level of the spinal cord. Single 5-µl volumes of drug solutions were administered. At the 
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end of the experiment, a laminectomy was performed to verify the location of the 
cannula tip. 
Effects of naftopidil on bladder activity 
   Two hours after MCAO, the effects of increasing doses of i.v., i.c.v., or i.t. naftopidil 
on cystometrography were investigated in conscious CI rats. Naftopidil was given to CI 
rats pretreated with RTX or to CI rats without injection of RTX (RTX-CI and CI rats, 
respectively) at 1-hour intervals. All rats were placed in a restraining cage.  
Data analysis 
   Data are expressed as a mean plus or minus the standard error of the mean (SEM). 
Statistical comparisons were performed by means of one-way or two-way repeated 
measures analysis of variance (ANOVA), with subsequent individual comparisons 
conducted with the aid of Fisher’s PLSD test. The Mann Whitney U-test or Wilcoxon 
signed-ranks test was used for comparison of the two groups. A level of p < 0.05 was 
considered statistically significant. 
 
RESULTS  
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   Bladder capacity was markedly reduced 2 hours after MCAO in both RTX-CI and 
CI rats, and it remained consistently below half of the pre-occlusion capacity (Fig. 1). 
No significant differences were found in bladder capacity or bladder contraction 
pressure between RTX-CI and CI rats. No residual volume was recognized in either 
group. 
Effects of i.v. administration of naftopidil 
   Intravenous naftopidil (2.6x10-1 ~ 2.6x103 nM/kg) significantly increased bladder 
capacity in CI rats (p <0.01) without any significant change in bladder contraction 
pressure or increase in residual volume (Fig. 2, 3). However, naftopidil had no effects 
on bladder capacity in RTX-CI rats (Fig. 3, 4). Significant differences were recognized 
in changes in bladder capacity between RTX-CI and CI rats (2.6x10-1~2.6x103 nM/kg; p 
<0.01 ~ 0.05).  
Effects of i.c.v. administration of naftopidil 
   Intracerebroventricular naftopidil did not elicit detectable changes in bladder 
capacity or bladder contraction pressure in CI rats (Fig. 5). A high dose (1.3x10 nmol) 
of naftopidil increased residual volume. 
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Effects of i.t. administration of naftopidil 
   Intrathecal naftopidil (1.3x10-3 ~ 1.3x10-1 nmol) significantly increased bladder 
capacity in CI rats (p< 0.01 ~ 0.05; Fig. 6). A high dose (1.3x10-1 nmol) of naftopidil 
increased residual volume without significance. On the contrary, intrathecal naftopidil 
did not change any parameters in RTX-CI rats (Fig. 6, 7).  
 
DISCUSSION 
   The data in the present study showed that intravenous or intrathecal naftopidil 
enlarged the bladder without decreasing bladder contraction pressure or increasing 
residual volume in C-fiber-intact CI rats. In contrast, naftopidil did not enlarge the 
bladder in C-fiber-desensitized CI rats, supporting the hypothesis that this α1-AR 
blocker improves detrusor overactivity by inhibition of the C-fiber afferent. This effect 
might depend on C-fiber afferent effects in the spinal cord rather than in the brain. 
   The slow development of detrusor overactivity following spinal cord injury is 
mediated by a reorganization of reflex connections [de Groat et al., 1990]. The afferent 
limb of the micturition reflex consists of C fibers in chronic spinal cats, which also 
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seems to be true in humans with spinal cord injury [Geirsson et al., 1995]. In patients 
with suprapontine lesions, such as those resulting from cerebrovascular accidents, 
dementia and Parkinson’s disease, cortical or diencephalic-mediated timing of the 
on-off switching mechanism is impaired, leading to detrusor overactivity [Bosch, 1999]. 
Detrusor overactivity in rats with cerebral infarction may be explained by impairment of 
this suprapontine regulatory system. C-fiber bladder afferents are not related to the 
development of detrusor overactivity caused by CI. Therefore, detrusor overactivity was 
recognized in C-fiber-desensitized rats as well as in C-fiber-intact rats in the present 
study. 
   There are a few clinical reports concerning the usefulness of α1-AR blockers on 
detrusor overactivity caused by neurological diseases [Jensen, 1981; Swierzewski et al., 
1994; Yasuda et al., 1996]. Prazosin, a non-selective α1-AR blocker, has been reported 
to be a valuable tool for neurogenic bladder [Jensen, 1981]. This agent diminished 
uninhibited detrusor contraction and increased bladder capacity. Terazosin has been 
shown to work to increase bladder capacity in spinal cord injured patients with detrusor 
overactivity [Swierzewski et al., 1994]. Urapidil has also been shown to be effective for 
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decreasing detrusor overactivity and daytime urinary frequency [Yasuda et al., 1996]. At 
present no definitive conclusions can be drawn on the efficacy of α1-AR blockers in the 
treatment of neurogenic bladder. The present study provides further basic information 
about an α1-AR blocker available for neurogenic storage dysfunction. 
   The smooth muscle contraction in infravesical part of the human lower urinary tract, 
and in particular the prostate are mediated largely, if not exclusively, by the α1A-AR 
subtype [Price et al., 1993; Yazawa and Honda et al., 1993; Marshall et al., 1995]. 
However, which subtype is related to storage symptoms and how α1-AR blockers work 
to improve detrusor overactivity remain a topic of controversy. In studies with 
α1d-knockout mice, the α1D-AR subtype has been suggested to play a significant role 
in regulating bladder function and it is likely to contribute to the development of storage 
symptoms [Chen et al., 2005]. Subtype analysis carried out in men indicated that the 
α1a- and 1d-AR mRNAs in the detrusor were expressed at a superimposable low 
density [Sigala et al., 2004]. In the trigone, the most expressed subtype was the α1a-AR. 
Studies on human normal and obstructed bladders did not show any differences in term 
of α1-AR subtype mRNA expression and function [Nomiya and Yamaguchi et al., 
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2003], suggesting that in patients with BOO, the detrusor overactivity involving 
α1-ARs could be mediated by extra-bladder localization of these receptors. The 
α1d-AR subtype is expressed in the detrusor, peripheral ganglia, and spinal cord in 
humans and rats [Somogyi et al., 1995; Malloy et al., 1998; Smith et al., 1999; Hampel 
et al., 2002]. α1d-AR was the predominant receptor subtype (present at twice the level 
of the other α1-AR subtypes) in sacral ventral motor neurons and autonomic 
parasympathetic pathways [Smith et al., 1999]. Sugaya et al [2002] reported that 
intrathecal injection of naftopidil, an α1A- and α1D-AR blocker (a relatively selective 
α1D-AR subtype) transiently abolished isovolumetric bladder contraction, although the 
interval and amplitude were unchanged after the reappearance of contractions in 
urethane-anesthetized rats. They suggested that naftopidil blocked the spinal afferent 
limb of the micturition reflex. The present study also revealed the inhibitory effect of 
intrathecal naftopidil on the micturition reflex of conscious rats. Bladder contraction 
pressure did not decrease after a high dose of naftopidil, meaning that this agent could 
not block descending efferent signal to the lower urinary tract at the level of the 
lumbosacral cord.  
 16
   The distribution patterns of mRNA encoding the α 1a-, 1b and 1d-AR subtypes were 
determined by in situ hybridization in the rat brain [Day et al., 1997]. The expression 
pattern of α1a mRNA was found to be widespread throughout the rat central nervous 
system. Supraspinal α 1-ARs are involved in the control of micturition reflex [Bao et al., 
2002]. I.c.v. administration of nonselective or selective α 1A-AR blocker has been 
reported to produce an inhibitory effect on micturition reflex, whereas α1B- and 1D-AR 
blockers have no effect. These findings suggest that central α1A-AR has an excitatory 
influence on the bladder activity. In the present study residual volume increased after a 
high dose of naftopidil, meaning that this agent could suppress micturition reflex at the 
supraspinal level via α1A-AR. 
   Vanilloid (capsaicin) receptors have been reported to exist in the brain stem (sensory 
nuclei), dorsal horn, dorsal root, and trigeminal and nodose ganglia other than 
peripheral sensory nerves (C-fiber afferents) [Szallasi et al., 1995]. RTX, which has a 
structure similar to that of capsaicin and acts as an ultra-potent capsaicin analogue, is 
highly specific for small-diameter sensory neurons, notably those with C-fibers. A large 
dose of RTX produces long-lasting but reversible suppression (desensitization) of the 
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activity of C-fibers. RTX, as well as capsaicin, has been used as a valuable tool to 
investigate the role of C-fiber afferents in the micturition reflex or nociceptive pathway 
[Tanaka et al., 2003]. Subcutaneous (systemic) RTX treatment depletes 
vanilloid-binding sites from the brain stem, spinal cord, and peripheral nerves. 
Therefore, the inhibitory effect of intravenous naftopidil on the overactive bladder does 
not necessarily depend on the suppression of C-fiber bladder afferents. However, in the 
present study intravenous and intrathecal administration of naftopidil improved the 
detrusor overactivity in CI rats but had no effect on RTX-CI rats, indicating that this 
α1-AR blocker improves detrusor overactivity by inhibiting C-fiber-mediated sensory 
input from the lower urinary tract at the lumbosacral spine. To our knowledge, the 
possibility that systemic (oral or intravenous) administration of α1-AR blockers could 
exert these therapeutic effects via suppression of C-fiber afferents in the spine has never 
been proven. 
 
CONCLUSIONS 
   The present study demonstrates that the α1-AR blocker naftopidil enlarges the 
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bladder via suppression of C-fiber afferents in the lumbosacral spine. This result may 
explain the clinical findings that α1-AR blockers are effective for treating storage 
symptoms.  
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FIGURE LEGENDS 
Figure 1. Mean influence ± SEM of left middle cerebral artery occlusion (MCAO) on 
bladder capacity in rats without pretreatment (A) or with pretreatment with 
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resiniferetoxin (B) 2 hours after occlusion. Double asterisks indicate p <0.01 vs. bladder 
capacity before MCAO. 
Figure 2. Representative cystometrogram showing the effects of intravenous 
administration of naftopidil (2.6, 2.6x102 nM/kg) in cerebral infracted rats. The bladder 
contraction interval decreased after cerebral infarction. Naftopidil increased the bladder 
contraction interval. 
Figure 3. Log dose-response curves of mean effects ± SEM on bladder capacity (A) and 
bladder contraction pressure (B), expressed as percent change after intravenous 
administration of increasing naftopidil doses of 2.6x10-1 to 2.6x103 nM in 6 cerebral 
infarcted (CI) rats without pretreatment (squares) or with pretreatment with 
resiniferetoxin (triangles). Single and double asterisks indicate p <0.05 and p <0.01, 
respectively, versus CI rats with pretreatment with resiniferetoxin (triangles).  
Figure 4. Representative cystometrogram showing the effects of intravenous 
administration of naftopidil (2.6, 2.6x102 nM/kg) in cerebral infarcted rats pretreated 
with resiniferatoxin. The bladder contraction interval decreased after cerebral infarction. 
Naftopidil did not increase the bladder contraction interval. 
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Figure 5. Log dose-response curves of mean effects ± SEM on bladder capacity (A), 
bladder contraction pressure (B), and residual volume (C), expressed as percent change 
after intracerebroventricular administration of increasing naftopidil doses of 1.3x10-2 to 
1.3x10 nmol in 6 cerebral infarcted rats without pretreatment (squares) or with 
pretreatment with resiniferetoxin (triangles). A high dose (1.3x10 nmol) of naftopidil 
increased residual volume. Double asterisks indicate p <0.01 versus CI rats with 
pretreatment with resiniferetoxin. 
Figure 6. Log dose-response curves of mean effects ± SEM on bladder capacity (A), 
bladder contraction pressure (B), and residual volume (C), expressed as percent change 
after intrathecal administration of increasing naftopidil doses of 1.3x10-3 to 1.3x10-1 
nmol in 6 cerebral infarcted (CI) rats without pretreatment (squares) or with 
pretreatment with resiniferetoxin (triangles). Single and double asterisks indicate p<0.05 
and p <0.01, respectively, versus CI rats with pretreatment with resiniferetoxin.  
Figure 7. Representative cystometrogram showing the effects of intrathecal 
administration of naftopidil (1.3x10-2, 1.3x10-1 nmol) in cerebral infarcted rats 
pretreated with resiniferatoxin. The bladder contraction interval decreased after cerebral 
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infarction. Naftopidil did not increase the bladder contraction interval. 
